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1. Introduction
Not so long ago, everything looked very simple, as the EGF
receptor (EGFR) was thought to sit on the cell surface and
wait for the incoming ligand to bind. Upon binding of EGF,
the receptors dimerized and the cytoplasmic tails, containing
the kinase domains, activated each other by transphosphory-
lation. The phosphorylated tyrosines, usually six, then served
as docking sites for the e¡ector molecules, normally other
kinases or enzymatically sterile adaptor proteins. They further
conveyed the message to the machinery involved in cell pro-
liferation and di¡erentiation. The speci¢city of the signaling
was seen to be dictated primarily by the nature of the ligand
and the receptor with further electiveness built into the inter-
actions between the cytoplasmic ‘business’ component of the
receptor and its e¡ectors. The command lines were viewed as
separate rows of arrows from the cell surface to the interior.
The cessation of signaling was marked by the uptake of the
receptor by the endocytic system and by its demise in the
lysosomes.
It was soon apparent that something else was taking place
as well. One of the curious observations in need of clari¢ca-
tion was the capacity of EGFR to carry on its mitogenic
functions even when its major phosphorylatable tyrosines
were eliminated [1]. There was also the unresolved question
of what the receptor was doing during transit to endosomes
and lysosomes; after all, during this trip in the cytosolic
vesicles, the receptor exposes its activated cytoplasmic tail
into a sea of putatively free-£oating e¡ector molecules [2].
In some cells, moreover, tickling with the receptor implied
the tolling of apoptotic death bells, quite unexpected of a
protein thought to be dedicated to coaching its e¡ectors
into promoting cell proliferation and di¡erentiation [3]. And
still looming in the background was the question of how the
speci¢c outcomes in various types of cells are generated, given
the apparently limited number of options inherent from the
structure of the receptor and receptor/e¡ector complexes. In
other words, where are the ‘missing’ determinants of speci¢c-
ity?
In this issue of FEBS Letters, three articles explore some of
these lesser known facets of EGFR. First, relating to deter-
minants of speci¢city from EGFR signaling, Jang et al. [4]
show that PLCQ1 (one of the downstream e¡ectors of
EGFR) colocalizes with the receptor in caveolae. These are
the sites where PIP2, the substrate of PLCQ1, is also concen-
trated and this colocalization is critical for the signaling from
PLCQ1. Secondly, Ho«gnason et al. [5] show that an elevated
level of EGFR in certain cells leads to apoptosis in a manner
that depends on the kinase activity of the receptor and which
is enhanced by blocking the Ras pathway. In the third paper,
Bae et al. [6] show that EGFR is a substrate for caspases and
suggest that proteolytic inactivation of the receptor is a crucial
part of a general apoptotic signaling cascade.
2. EGFR and caveolae
Caveolae are currently viewed as specialized membrane do-
mains in which signaling pathways, or at least their very prox-
imal components, sit preorganized waiting for the ligand to
call them to action. As to the EGFR, it has already been
known for some time that in unstimulated cells EGFRs are
concentrated in the caveolae [7,8], in which also EGFRs’
downstream adaptors and e¡ectors are enriched. It has also
become clear that many of the critical steps in the EGFR
pathway (signaling, activation of the receptor itself, phosphor-
ylation of its substrates, recruitment of the adaptors and ki-
nases, and activation of MAPKs) take place in the caveolae
[9].
The exit of the EGFR from the caveolae and the subse-
quent engulfment in the coated pits and endosomes is not
only a prelude to the down-regulation of the signal but also
part of active signaling. Mineo et al. [8] have put forward a
scheme in which the activated receptor in transit could, in its
various locations, induce di¡erent sets of signals. In this view,
the question of the ‘missing’ determinants of speci¢city is
partially resolved by envisioning a migratory receptor (in
complex with e¡ectors) that arrives at various stations (cav-
eolae, bulk membrane, coated pits, endosomes) in which dif-
ferent types of signaling machineries are activated depending
on the local ‘ecology’. This new model is in concert with the
idea proposed by Vieira et al. [10], which is based on studies
indicating that only part of the signaling e¡ects of an acti-
vated EGFR become manifested in endocytosis-de¢cient cells.
In this vision, ligands have evolved to regulate their signals by
EGFR tra⁄cking [11]. Just recently, the ¢rst components of
the molecular machinery that integrate EGFR signaling and
receptor tra⁄cking have come to light [12].
A new piece of evidence in support of the scheme under-
lining the importance of the spatial aspects of the signaling
pathway is now provided by Jang et al. [4]. They demonstrate
that, in response to EGF, PLCQ is moved to and becomes
phosphorylated in caveolae. Pretreatment with MLCD (a cho-
lesterol-binding compound that delocalizes PIP2 from the cav-
eolae) led to inhibition of PtdIns turnover. However, it did
not diminish phosphorylation of PLCQ. Thus, colocalization
of the substrate and the enzyme in the caveolae is a prereq-
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uisite for PLCQ-mediated PtdIns turnover, one of the major
signaling events induced by EGFR. Interestingly and ¢tting
with the results of Jang et al., Haugh et al. [13] have recently
shown that EGFR signaling through the PLC pathway at the
cell surface is spatially restricted at a point between PLCQ1
phosphorylation and PIP2 hydrolysis. Obviously, there is still
a lot of uncharted territory here. According to a recent sug-
gestion, EGF stimulates redistribution of an entire signaling
complex involving Ras, Raf-1, Mek and MAPK from the
caveolae to the endosomes in which the rest of the signaling
events could take place [14].
3. EGFR and apoptosis
EGFR is mostly referred to as a regulator of cell prolifer-
ation, migration and di¡erentiation. For a long time it has
been known, however, that in some cell types EGFR can also,
‘paradoxically’, mediate apoptotic signals. It is seen especially
in cells overexpressing EGFR (for instance A431) and in some
tumor cells. However, it also occurs in normal epithelial cells
and organisms. Its mechanism is poorly understood. EGF-
induced attenuation of cell adhesion [15], EGF acting as a
dedi¡erentiation factor for some cells [16] and down-regula-
tion of EGFR in response to EGF [17] have all been sug-
gested as possible mechanisms.
In this issue, Ho«gnason et al. [5] have studied the mecha-
nism of the ‘paradoxical’ apoptosis-inducing e¡ect of EGF
stimulation. They show that experimental increases in the lev-
el of EGFR expression predictably lead to apoptosis in a
variety of cell types. This e¡ect is dependent on tyrosine ki-
nase but does not require autophosphorylation of the recep-
tor. Blocking of the Ras signaling augments the apoptotic
e¡ect, most likely by impairing Akt activation. As a mecha-
nism, it is proposed that in EGFR-overexpressing cells a
threshold may be reached, beyond which the balance is tipped
from growth gain to apoptosis due to misregulation of the
signaling circuitry. Clearly, a role for EGF in anti-prolifera-
tive signaling and apoptosis is gaining ground. One of the
important still unresolved questions is whether EGF-induced
apoptosis is due to anoikis [18] or is independent of cell ad-
hesion, as proposed by Ho«gnason et al. Further studies are
needed to delineate the stoichiometries of EGFR and its ef-
fectors as determinants of proliferation vs. apoptosis.
It is noteworthy that EGF-induced apoptosis also occurs in
normal cells and is part of ‘normal’ physiology. In these cases,
excessive signaling may not be as credible an explanation as in
tumor cells. Could it be that in these cells, similar to the
scheme proposed by Mineo et al. [8], the receptor stops by
‘stations’ in which everything is geared (unlike in other cells)
to induce apoptosis instead of e.g. di¡erentiation? Such a
predisposition to apoptosis upon EGF-binding could be due
to either hardwiring that is inherent in the di¡erentiated phe-
notype of the cell, or to coordinated cross-talk between di¡er-
ent signaling pathways.
Another window to view the fates and ways of EGFR and
its relation to apoptosis is the report by Bae et al. [6], in which
EGFR is shown to be a target of an incapacitating cleavage
by apoptotic caspases 1, 3 and 7. The authors suggest that this
may be the way the anti-apoptotic signals, normally emanat-
ing from the EGFR and including possible activation of PI3K
and PKC-K, are abrogated. It remains to be explored, how-
ever, whether the inactivation of the anti-apoptotic mecha-
nisms plays only a minor role in the play of apoptosis or
whether incapacitating the mitotic receptor in a way analo-
gous to growth factor withdrawal could be a more proximate
factor in the initiation of the death cascade.
Curiously, the growth inhibitory e¡ect of EGF on A431
cells is one of the early observations on the e¡ects of EGF
on cultured cells [19]. Apart from the current results there are
also some other recent data that help us to make sense of this
‘anomaly’. Namely, EGF, together with interferon Q, induces
(in a STAT dependent manner) the expression of the caspase
1 enzyme and the cell cycle inhibitor P21WAF1/CIP1, which
are involved in apoptosis and growth inhibition, respectively
[20,21].
4. Location de¢nitely plays a role
It is becoming increasingly clear that not only the intrinsic
properties of the EGFR prior, upon, and subsequent to its
activation by the ligand-binding, but also its position relative
to the various locations that are available to it are of impor-
tance as to what its impact will be on the cell phenotype. One
aspect of this di¡erential e¡ect of the location on the receptor
function is already well established, i.e. di¡erential response in
di¡erent cell types. It is evident that, in the future, more dis-
criminating approaches (a¤ la mode functional topography) are
needed in which the di¡erential functioning of not only
EGFR but also other receptors in various cell locations and
under various conditions is scrutinized.
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